Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine and Pazopanib in Advanced Urothelial Carcinoma
NCT01622660Phase 2Terminated
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jun 2012
- Primary completion
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pazopanib in urothelial carcinoma (UC), sponsored by Memorial Sloan Kettering Cancer Center. Started Jun 2012; status: terminated.
02
Drugs
pazopanib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT01622660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01622660.